Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing ...

In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...

The DapaTAVI trial assessed the benefits of dapagliflozin in patients discharged after TAVI with a history of heart failure plus 1 of the following comorbidities: LVEF ≤40%, diabetes, or renal ...

Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

The study showed that treatment with Farxiga (dapagliflozin) led to an 18% reduction in cardiovascular death or worsening heart failure in patients with both mildly reduced and preserved ejection ...

As heart failure patients, the TAVI population studied already is recommended to be treated with an SGLT2 inhibitor, noted ...

Dapagliflozin is indicated for both type 2 diabetes and heart failure. It can do the following: improve management of blood sugar and reduce the risk of hospitalization for heart failure in adults ...

Type 2 diabetes mellitus (T2DM) is a major public health challenge in India, with an estimated 101 million individuals ...

"Treating heart failure with an LVEF of 40% or greater ... That includes AstraZeneca's Farxiga (dapagliflozin) and Eli Lilly/Boehringer Ingelheim's Jardiance (empagliflozin) – both SGLT2 ...